Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569726 | 0.98 | CYP2D6 (0.36) | CYP2D6CYP1A2ESR1ESR2CYP3A4 | |
| SCHEMBL14626815 | 0.86 | CYP2D6 (0.38) | CYP2D6CYP1A2ESR1ESR2CYP3A4 | |
| SCHEMBL13021351 | 0.83 | CYP1A2 (0.44) | CYP2D6CYP1A2TDP1PABPC1APOBEC3A | |
| SCHEMBL7735125 | 0.83 | CYP1A2 (0.49) | CYP2D6CYP1A2TDP1PABPC1APOBEC3A | |
| SCHEMBL2379725 | 0.83 | CYP1A2 (0.49) | CYP2D6CYP1A2TDP1PABPC1APOBEC3A | |
| SCHEMBL899386 | 0.82 | CYP1A2 (0.33) | CYP2D6CYP1A2 | |
| SCHEMBL23815709 | 0.79 | CYP1A2 (0.35) | CYP2D6CYP1A2 | |
| SCHEMBL8369196 | 0.78 | CYP1A2 (0.33) | CYP2D6CYP1A2 | |
| SCHEMBL8911086 | 0.76 | TDP1 (0.43) | CYP2D6ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL4890514 | 0.76 | ESR1 (0.43) | CYP2D6CYP1A2ESR1ESR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637526-B1 | CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | TOKUYAMA CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7754903-B2 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | TOKUYAMA CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | TOKYUYAMA CORPORATION (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637526-A1 | CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | TOKUYAMA CORPORATION (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | PFN1, FSCN1, PFDN1 | CYP2D6 498/4885CYP1A2 597/4885ESR1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.